• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Oxervate (cenegermin-bkbj)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Oxervate (cenegermin-bkbj)

  • Profile

Profile

Contact Information

Contact: Dompe Pharmaceuticals
Website: https://oxervate.com/

Currently Enrolling Trials

    Show More

    General Information

    Oxervate (cenegermin-bkbj) is a recombinant human nerve growth factor.

    Oxervate is specifically indicated for the treatment of neurotrophic keratitis. 

    Oxervate is supplied as a solution for topical ophthalmologic administration. Contact lenses should be removed before applying Oxervate and may be reinserted 15 minutes after administration. Instill one drop of Oxervate in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks. If a dose is missed, treatment should be continued as normal, at the next scheduled administration. If more than one topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer Oxervate 15 minutes prior to using any eye ointment, gel or other viscous eye drops.

    Mechanism of Action

    Oxervate (cenegermin-bkbj) is a recombinant human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.

    Side Effects

    Adverse effects associated with the use of Oxervate may include, but are not limited to, the following:

    • eye pain
    • ocular hyperemia
    • eye inflammation
    • increased lacrimation

    Clinical Trial Results

    The FDA approval of Oxervate was based on two double-masked, randomized, multi-center, controlled clinical trials. Both trials studied Oxervate monotherapy (20 mcg/mL) as compared to vehicle, a proxy for preservative-free artificial tears, among patients with moderate or severe neurotrophic keratitis. Study NGF0212 (REPARO), which was conducted in Europe, randomized 52 patients to each group. After eight weeks, approximately 72% of patients in the treatment group were completely healed. This study had a long-term follow up. In REPARO, approximately 80% of patients who healed during the eight-week treatment period remained healed after one year. Study NGF0214, conducted in the U.S., randomized 24 patients to each group, and 65.2% of treated patients were completely healed after 8 weeks.

    Approval Date: 2018-08-01
    Company Name: Dompe Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing